このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Rhythm Biosciences マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

David Atkins

最高経営責任者

AU$409.2k

報酬総額

CEO給与比率	12.1%
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	6yrs

経営陣の近況

Recent updates

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Dec 02

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Jul 19

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Mar 03

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

Dec 03

CEO報酬分析

Rhythm Biosciences の収益と比較して、David Atkins の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	AU$409k	AU$49k	-AU$7m

報酬と市場: Davidの総報酬 ($USD 275.68K ) は、 Australian市場 ($USD 309.27K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: CEOの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

David Atkins (59 yo)

less than a year

在職期間

AU$409,243

報酬

Dr. David Atkins, MBA, Ph. D., serves as Chief Executive Officer of Rhythm Biosciences Limited since May 13, 2024. He was Director of Cynata Therapeutics Limited from July 01, 2022 until November 2023. He...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Atkins	Chief Executive Officer	less than a year	AU$409.24k	データなし
Guy Carisbrooke	Financial Controller	less than a year	AU$178.96k	データなし
Andrea Steele	General Counsel & Joint Company Secretary	2.6yrs	データなし	データなし
James Barrie	Joint Company Secretary	less than a year	データなし	データなし

0.8yrs

平均在職期間

経験豊富な経営陣: RHYの経営陣は経験豊富とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Otto Buttula	Non-Executive Chairman	4.9yrs	AU$369.11k	14.64% A$ 2.2m
Louis Panaccio	Non-Executive Director	7.1yrs	AU$66.86k	0.43% A$ 65.8k
Susan MacLeman	Independent Deputy Chair	1.7yrs	AU$87.74k	データなし
Trevor Lockett	Non-Executive Director	7.3yrs	AU$227.26k	0.68% A$ 102.4k

6.0yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: RHYの取締役会は経験豊富であると考えられます ( 5.8年の平均在任期間)。

Rhythm Biosciences マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

Executive Chairman recently bought AU$248k worth of stock

Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director

Recent updates

Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Share price stability

New major risk - Financial position

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million.

Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million.

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

New major risk - Share price stability

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

New minor risk - Shareholder dilution

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

New minor risk - Financial data availability

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

Executive Chairman recently bought AU$248k worth of stock

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Eduardo Vom Retires as A Non-Executive Director of Rhythm Biosciences Limited

Less than half of directors are independent

Rhythm Biosciences Limited, Annual General Meeting, Nov 29, 2022

Rhythm Biosciences Limited Appoints Paul Smith as Chief Financial Officer

Executive Chairman recently sold AU$6.5m worth of stock

Executive Chairman exercised options to buy AU$459k worth of stock.

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Rhythm Biosciences Limited Advances Platform Expansion with Other Cancers

Less than half of directors are independent

Rhythm Biosciences Announces the Statistical Analysis Outcomes of Its Clinical Trial (Study 7) as Verified by Rhythm's Third-Party Statisticians for ColoSTAT ®

Rhythm Biosciences Ltd Announces Executive Changes

Rhythm Biosciences Limited announced that it expects to receive AUD 6.532651 million in funding

Rhythm Biosciences Limited Completes Recruitment for Clinical Trial (Study 7)

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Non-Executive Director David White has left the company

Rhythm Biosciences Adds Sonic Clinical Services to Colostat Clinical Trial

Rhythm Biosciences Betters ColoSTAT Results

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

New 90-day high: AU$1.64

Rhythm Biosciences Limited Expands ColoSTAT Clinical Trial to Tenth Site

New 90-day high: AU$1.56

Rhythm Advances ColoSTAT® Study 7, adding 2 New Clinical Trial sites

New 90-day high: AU$1.38

New 90-day high: AU$0.88

Rhythm Biosciences Limited Appoints Biotem Limited as the Global Manufacturer of its ColoSTAT® Test-Kit

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

New 90-day high: AU$0.28

New 90-day high: AU$0.21

Rhythm Biosciences Limited Announces Rhythm Biosciences Limited Joins the ColoSTAT® Clinical Trial

New 90-day high - AU$0.20

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.627 million.

Rhythm Biosciences Limited announced that it expects to receive AUD 2.40675 million in funding

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24